The Senate Judiciary Committee today voted 16-5 to approve the Creating and Restoring Equal Access to Equivalent Samples Act (S. 974). The AHA-supported bill would allow generic drug manufacturers facing certain anticompetitive delay tactics to bring an action in federal court for injunctive relief. More than 45 organizations, including the AHA, last week urged the committee to support the legislation to “end the anticompetitive abuses utilized by some brand-name manufacturers, help restore the balance between innovation and affordability that Congress intended, and achieve the goal of more affordable prescription drugs.” The Congressional Budget Office estimates the legislation will save $3.8 billion over 10 years.

Related News Articles

Headline
The House Budget Committee today held a hearing on the Congressional Budget Office’s recent report on key design components and considerations for policymakers…
Headline
The Department of Health and Human Services aims to release proposed rules amending the physician self-referral (Stark law) regulations and safe-harbors under…
Headline
The Department of Health and Human Services Office for Civil Rights today published in the Federal Register its final rule concerning federal health care-…
Blog
Last week, researchers at RAND released a study that made broad claims about the prices that private insurers pay hospitals. The RAND authors relied on…
Headline
Sens. Bill Cassidy, R-La., Michael Bennet, D-Colo., Todd Young, R-Ind., Maggie Hassan, D-N.H., Lisa Murkowski, R-Alaska, and Tom Carper, D-Del., today…
Blog
Earlier this week, Politico published cherry-picked metrics from the recently released Moody’s Preliminary Medians for not-for-profit and public hospitals.